Back to search

Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli‐asparaginase or Erwinia‐asparaginase in childhood acute lymphoblastic leukemia (ALL)

Data up to Jan 2025

Published2005
Citations17
References27

Total Citations Per Year

Abstract

References (27)

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

1998 • 968 citations

Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

1998 • 772 citations

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

2000 • 634 citations

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

2004 • 466 citations

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

2000 • 462 citations

Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects

1961 • 460 citations

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer---Children's Leukemia Group phase 3 trial

2002 • 409 citations

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia

1999 • 356 citations

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1998 • 339 citations

Comparative pharmacokinetic studies of three asparaginase preparations.

1993 • 328 citations

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995

2000 • 322 citations

Toxicity of E. coli L-asparaginase in man

1970 • 290 citations

Childhood acute lymphoblastic leukaemia – current status and future perspectives

2001 • 266 citations

Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations

2005 • 225 citations

Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations

1997 • 217 citations

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations

1996 • 210 citations

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

2000 • 203 citations

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report

2000 • 200 citations

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

2002 • 125 citations

Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

2003 • 122 citations

L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure

2000 • 106 citations

Precursor-B-ALL with DH–JH gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14

2001 • 97 citations

Non‐randomised study comparing toxicity of escherichia coli and erwinia asparaginase in children with leukaemia

1990 • 84 citations

Prognostic Significance of Early Response to a Single Dose of Asparaginase in Childhood Acute Lymphoblastic Leukemia

1999 • 62 citations

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

2001 • 58 citations

The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?

2004 • 51 citations

Clonal Analysis of B-Cell Leukemias and Lymphomas using the Polymerase Chain Reaction for the Third Complementarity Determining Region of the IgH Gene: A Study of 75 Cases from Nagasaki Japan

1999 • 9 citations

Cited By (0)

Loading...
Minimal residual disease (MRD) measurement as a tool to compare the efficacy of… (2005) – Pediatric Blood & Cancer | Metascience Observatory Explorer